PUBLIC COMPANY
save$NKTRNEKTAR THERAPEUTICS
$NKTR42.22-3.12%San Francisco, CA, USupdated 3h ago
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
4
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase2A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
- phase2A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
- phase2Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
- phase3NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
- phase2A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
- phase1A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
- phase1A Study of LY3471851 in Participants With Psoriasis
- phase1A Study of LY3471851 in Participants With Eczema
🐶 Hiring Signal
News
- Jury awards Nektar $90M in suit against LillyNektar Therapeutics won $90 million in its lawsuit against Eli Lilly over a fractured licensing deal, a win for the biotech but a far smaller sum than was sought. Jurors in the US District Court ...endpoints · 10d ago
- STAT+: Lilly wins approval for once-weekly insulin shotThe FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.stat · 10d ago
- Nektar prevails in legal battle with Lilly over broken rezpeg partnershipNektar Therapeutics has been awarded $90 million in damages after a jury sided with the biotech, which had accused Big Pharma Eli Lilly of “botching” an analysis of their formerly partnered autoimm…biospace · 10d ago
- STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and morePresident Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion accessstat · 10d ago
- Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s dataNovo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.biopharma_dive · 10d ago
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczemaInfinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.biopharma_dive · 1mo ago
- Q32 bounces back to claim study success for alopecia drugNearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.biopharma_dive · 2mo ago
- Sanofi posts upbeat sales as R&D pressure buildsA string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.biopharma_dive · 5mo ago
Data sources
last refreshed 47m ago
Found something off?
comments(0)
5-min edit window · permanent after that